Table 1.
Patient Characteristics Among Average-Risk Adults With Bariatric and Metabolic Surgery (BMS) Followed by Multitarget Stool DNA (mt-sDNA) Use Compared to 1) Patients With BMS Followed by Screening Colonoscopy and No History of mt-sDNA Use and 2) Average-Risk Patients With mt-sDNA Use but No History of BMS
| Characteristic | mt-sDNA after BMS |
Screening colonoscopy after BMS |
Non-BMS mt-sDNAb |
P value mt-sDNA BMS cohort compared to |
|
|---|---|---|---|---|---|
| N = 365 | N = 139 | N = 1542 | Screening colonoscopy after BMS | Non-BMS mt-sDNAb | |
| Median age, years (IQR) | 61 (55–67) | 57 (51–64) | 67 (61–73) | <.0001 | <.0001 |
| Women, n (%) | 306 (84) | 99 (71) | 919 (60) | .002 | <.0001 |
| White race, n (%) | 357/362 (99) | 126/138 (91) | 1480/1521 (97) | .0002 | .18 |
| Current or former tobacco, n (%) | 162 (44) | 62 (45) | 760/1530 (50) | 1.00 | .07 |
| History of prior screening colonoscopy, n (%) | 209 (57) | NA | 906 (59) | - | .64 |
| History of any colorectal neoplasia at prior colonoscopy, n (%) | 14/209 (7) | NA | 144/862 (17) | - | .0001 |
| Presurgical BMI, kg/m2 (IQR)c | 44 (40–49) (N = 251) | 43 (38–48) (N = 138) | - | .14 | - |
| Roux-en-Y gastric bypass, n (%) | 297 (81) | 102 (74) | - | <.0001 | - |
| Sleeve gastrectomy, n (%) | 46 (13) | 19 (14) | - | ||
| Vertical band gastrectomy, n (%) | 13 (4) | 0 (0) | - | ||
| Other BMSa, n (%) | 9 (2) | 18 (13) | - | ||
| History of surgical revision, n (%) | 22/361 (6) | 6/137 (4) | - | .52 | - |
IQR, inter-quartile range.
mt-sDNA pts - Biliopancreatic diversion with duodenal switch (N = 4), Billroth II (N = 1), gastric plication (N = 1), and not otherwise specified (N = 3); Screening pts–Biliopancreatic diversion with duodenal switch (N = 14) and vertical sleeve (N = 4).
16 patients with mt-sDNA and prior BMS in this group were removed and analyzed only in the mt-sDNA after BMS group.
BMI data were available for 251 and 138 patients in the mt-sDNA after BMS and screening colonoscopy after BMS cohorts, respectively.